| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA627: Lenalidomide with rituximab for previously treated follicular lymphoma |
|
Medicine details |
|
| Medicine name | lenalidomide (Revlimid®) |
| Formulation | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg and 25 mg hard capsule |
| Reference number | 2434 |
| Indication | In combination with rituximab (anti-CD20 antibody) for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a) |
| Company | Celgene Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 18/12/2019 |
| NICE guidance | TA627: Lenalidomide with rituximab for previously treated follicular lymphoma |
| Commercial arrangement | PAS |